|Bid||498.00 x 800|
|Ask||500.00 x 800|
|Day's range||499.41 - 507.26|
|52-week range||383.12 - 553.29|
|Beta (5Y monthly)||0.83|
|PE ratio (TTM)||27.49|
|Earnings date||15 Jul 2022|
|Forward dividend & yield||5.80 (1.16%)|
|Ex-dividend date||11 Mar 2022|
|1y target est||568.52|
Investors are optimistic about Myriad Genetics (MYGN) owing to strong Q1 2022 results and growth in testing volumes.
Investors are optimistic about the robust performances of Amedisys' (AMED) Home Health and Hospice segments.
Distributor purchasing dynamics have an impact on IDEXX's (IDXX) CAG segment product sales.